@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP161436.RAjUnslI-KfFi7sg6QfqYTQej6K1sN3MU3etNchmuJnWo130_head { this: np:hasAssertion dgn-np:NP161436.RAjUnslI-KfFi7sg6QfqYTQej6K1sN3MU3etNchmuJnWo130_assertion; np:hasProvenance dgn-np:NP161436.RAjUnslI-KfFi7sg6QfqYTQej6K1sN3MU3etNchmuJnWo130_provenance; np:hasPublicationInfo dgn-np:NP161436.RAjUnslI-KfFi7sg6QfqYTQej6K1sN3MU3etNchmuJnWo130_publicationInfo; a np:Nanopublication . dgn-np:NP161436.RAjUnslI-KfFi7sg6QfqYTQej6K1sN3MU3etNchmuJnWo130_assertion a np:Assertion . dgn-np:NP161436.RAjUnslI-KfFi7sg6QfqYTQej6K1sN3MU3etNchmuJnWo130_provenance a np:Provenance . dgn-np:NP161436.RAjUnslI-KfFi7sg6QfqYTQej6K1sN3MU3etNchmuJnWo130_publicationInfo a np:PublicationInfo . } dgn-np:NP161436.RAjUnslI-KfFi7sg6QfqYTQej6K1sN3MU3etNchmuJnWo130_assertion { miriam-gene:5617 a ncit:C16612 . lld:C0006142 a ncit:C7057 . dgn-gda:DGNc9d7ef8d9cff057baf74d10d5fd2f7fc sio:SIO_000628 miriam-gene:5617, lld:C0006142; a sio:SIO_001121 . } dgn-np:NP161436.RAjUnslI-KfFi7sg6QfqYTQej6K1sN3MU3etNchmuJnWo130_provenance { dgn-np:NP161436.RAjUnslI-KfFi7sg6QfqYTQej6K1sN3MU3etNchmuJnWo130_assertion dcterms:description "[Both experimental studies and human sample/cohort-based investigations performed during the past decade have considerably widened our perception of PRL biology: i) there are now strong epidemiological arguments supporting the fact that circulating PRL is a risk factor for breast cancer, ii) in addition to the endocrine hormone, locally produced PRL has been documented in several human tissues; there is increasing evidence supporting the tumor growth potency of local PRL, acting via autocrine/paracrine mechanisms, in both rodent models, and human breast and prostate tumors, iii) the first functional germinal polymorphisms of the PRL receptor were recently identified in patients presenting with breast tumors, which involve single amino acid substitution variants exhibiting constitutive activity, iv) human PRL analogs have been engineered, which were shown in experimental models to down-regulate the effects triggered by local PRL (competitive antagonism) or by the constitutively active receptor variants (inverse agonism).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:20371569; prov:wasDerivedFrom dgn-void:befree-20140225; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:befree-20140225 pav:importedOn "2014-02-25"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP161436.RAjUnslI-KfFi7sg6QfqYTQej6K1sN3MU3etNchmuJnWo130_publicationInfo { this: dcterms:created "2014-10-02T12:33:27+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetrdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v2.1.0.0" . dgn-void:disgenetrdf pav:version "v2.1.0" . }